Business Context and Reporting Period
Company: Galectin Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 17, 2019
Reporting Period: Single event date (September 17, 2019)
Business Context: The registrant is a Nevada corporation with its principal executive office in Norcross, GA. Its common stock trades on The Nasdaq Capital Market under the symbol "GALT".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves as a notification of a press release issuance and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial position or operations are detailed in this specific filing. The document solely reports the issuance of a press release (Exhibit 99.1) on September 17, 2019.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release attached as Exhibit 99.1 but does not summarize its content, guidance, or outlook within the text of the 8-K.
Risks and Contingencies: No specific risks or contingencies are disclosed in this filing text.
Unusual Items: None reported in this filing text.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for the specific details of the event reported on September 17, 2019.
- Verify the company's current cash position and runway by consulting the most recent 10-Q or 10-K filing, as this 8-K contains no financial data.
- Confirm the trading status of the "GALT" ticker on The Nasdaq Capital Market.
- Check for any subsequent filings that may elaborate on the contents of the September 17, 2019 press release.